NATCOPHARM - IntraDay Trade Analysis with Live Signals

Last Updated Time : 05 Nov 25, 7:43 am

Html

Copy

IntraDay Trade Rating: 3.2

💹 Optimal Buy Price: ₹810–₹815 (near short-term support and below 50 DMA)

🎯 Profit Target: ₹835–₹845 (resistance zone near 50 DMA)

🛡️ Stop Loss: ₹800 (below recent support and psychological level)

📊 Exit Strategy if Already Holding: Consider exiting near ₹840 if RSI approaches 50 and MACD begins to flatten. Watch for price rejection near ₹845 and volume spikes.

✅ Positive

• 📈 Strong ROCE (31.8%) and ROE (27.5%) indicate efficient capital use
• 📉 Low P/E of 8.76 vs industry average of 33.1 suggests undervaluation
• 📉 PEG ratio of 0.06 indicates deep value relative to earnings growth
• 📊 Debt-to-equity ratio of 0.04 reflects financial prudence
• 📈 EPS of ₹93.7 supports strong earnings base

⚠️ Limitation

• 📉 RSI at 45.0 and MACD at -4.29 indicate weak momentum
• 📉 Stock trading below both 50 DMA and 200 DMA, showing bearish pressure
• 📉 FII holding declined by 1.43%
• 📉 Quarterly profit variation of -27.1% signals recent earnings pressure
• 📉 Volume today (3.71L) is slightly below 1-week average (3.82L)

🚫 Company Negative News

• 📉 No major negative news reported recently

📢 Company Positive News

• 📈 PAT of ₹464 Cr remains strong despite sequential decline
• 📊 DII holding increased slightly by 0.06%, showing marginal domestic support

🏭 Industry

• 💊 NATCOPHARM operates in the pharmaceutical sector, which is defensive and earnings-resilient
• 📈 Industry P/E of 33.1 supports long-term valuation potential

🧾 Conclusion

📌 NATCOPHARM presents a cautious intraday opportunity today with strong fundamentals and value indicators, but weak momentum and technical pressure. Traders may consider entering near ₹812 with a target of ₹840 and stop loss at ₹800. If already holding, monitor RSI and MACD for exit signals near resistance.

Let me know if you'd like a side-by-side comparison with other pharma stocks like Divi’s or Laurus Labs for sharper intraday setups.